Riccardo Braglia
Vice Chairman and Chief Executive Officer @ 3B Future Health Fund
Riccardo Braglia is a Series A investor at 3B Future Health Fund focused on Biotechnology and Health Care. Riccardo Braglia - Vice Chairman and Chief Executive Officer @ 3B Future Health Fund
- Total investments:
- 8
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Riccardo Braglia invests in
Stages Riccardo Braglia invests in
Countries Riccardo Braglia invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $5M–$5.8M
- Series B
- $9.5M–$86M
Investment Focus
Industry
- Biotechnology 3 (38%)
- Health Care 2 (25%)
- Therapeutics 2 (25%)
- B2B 1 (13%)
- SaaS 1 (13%)
Stage
- Series A 2 (25%)
- Series B 2 (25%)
- Seed 1 (13%)
- Convertible Note 1 (13%)
Country
- Switzerland 2 (25%)
- United States 2 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $85.7M / Series B / Jun 20, 2024 | ||
| Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $5M / Series A / Apr 12, 2023 | ||
| iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $5.8M / Series A / Jul 14, 2020 | ||
| BSAMPLY is an innovative business-to-business collaboration platform with a mission to digitalize the fashion, interior and raw material industries. Founded in 2017 in Los Angeles by Andrea Fiume, BSAMPLY is designed to make every step of sales, communication and order process between buyers and suppliers faster and easier. In July of 2022, Bsamplybecame part of Dedagroup Stealth Spa. Whether it be simply for showcasing products and sourcing samples or managing the entire order and design process, Bsamply offers the technology and solution to meet both needs through one common platform and one shared language.Learn more about Dedagroup Stealth: https://www.dedagroupstealth.com/home | $600K / Seed / Mar 20, 2020 | ||
| BSAMPLY is an innovative business-to-business collaboration platform with a mission to digitalize the fashion, interior and raw material industries. Founded in 2017 in Los Angeles by Andrea Fiume, BSAMPLY is designed to make every step of sales, communication and order process between buyers and suppliers faster and easier. In July of 2022, Bsamplybecame part of Dedagroup Stealth Spa. Whether it be simply for showcasing products and sourcing samples or managing the entire order and design process, Bsamply offers the technology and solution to meet both needs through one common platform and one shared language.Learn more about Dedagroup Stealth: https://www.dedagroupstealth.com/home | $450K / Convertible Note / Jun 26, 2019 | ||
| Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. | $32.6M / Series B / Nov 12, 2018 | ||
| BSAMPLY is an innovative business-to-business collaboration platform with a mission to digitalize the fashion, interior and raw material industries. Founded in 2017 in Los Angeles by Andrea Fiume, BSAMPLY is designed to make every step of sales, communication and order process between buyers and suppliers faster and easier. In July of 2022, Bsamplybecame part of Dedagroup Stealth Spa. Whether it be simply for showcasing products and sourcing samples or managing the entire order and design process, Bsamply offers the technology and solution to meet both needs through one common platform and one shared language.Learn more about Dedagroup Stealth: https://www.dedagroupstealth.com/home | $570K / Convertible Note / Nov 10, 2017 | ||
| Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. | $9.5M / Series B / Sep 05, 2017 |
Co-Investors
About 3B Future Health Fund
Helsinn Investment Fund S.A. is a Luxembourg fund focused on early-stage investments in areas of high unmet patient need.
3B Future Health Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Carlos von Bonhorst
Strategic Consultant
|
|||
Marianne Bjordal
Partner
|
|||
|
Riccardo Braglia
Vice Chairman and Chief Executive Officer
|
|||
Francesco Granata
Consultant
|
|||
Karin Hehenberger
Medical and Scientific Consultant
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Riccardo Braglia invest in?
Riccardo Braglia invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Riccardo Braglia's check size?
Riccardo Braglia typically joins rounds of $5M–$5.8M at Series A and $9.5M–$86M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Riccardo Braglia participates in.
How do I contact Riccardo Braglia?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Riccardo Braglia last invest?
The most recent investment recorded for Riccardo Braglia closed in Jun 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
